

Open Peer Review on Qeios

Anti-PD-L1 Monoclonal Antibody LY3300054

National Cancer Institute

Source

National Cancer Institute. <u>Anti-PD-L1 Monoclonal Antibody LY3300054</u>. NCI Thesaurus. Code C128138.

A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody LY3300054 binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.

Qeios ID: 71SVYO · https://doi.org/10.32388/71SVYO